Where scientific depth meets operational scale
From early in vivo efficacy studies to IND-enabling programs, Sai Life Sciences’ in vivo pharmacology platform delivers comprehensive preclinical services across diverse therapeutic areas. As a trusted in vivo pharmacology CRO in India, we operate a state-of-the-art vivarium accredited by AAALAC and OLAW, supporting over 300+ studies annually and utilizing more than 200 validated and custom-developed disease models for drug testing.
We specialize in pharmacokinetics and pharmacodynamics (PK/PD) studies, in vivo target validation, and PK/PD modeling and simulation services, with a focus on data quality, translational insight, and speed to decision. All research is conducted in compliance with CCSEA guidelines and IAEC-approved protocols, covering both GLP and non-GLP in vivo studies. Whether you're looking for standard or custom rodent models for pharmacology, our team offers unmatched flexibility, scientific depth, and ethical rigor. As an experienced in vivo PK/PD CRO, we are committed to long-term collaboration and deliver data that’s ready to move your molecule forward.
Clients
Therapeutic Areas
Disease Models
Studies Conducted Annually
Our models encompass a diverse array of therapeutic areas, including syngeneic tumor models, STZ-induced diabetes, and neurobehavioral assays. Each study is meticulously designed to fit its context, involving the selection of relevant models, clear endpoint definition, and optimization of readouts to guide development strategy.
• Immuno-oncology & Oncology in vivo models
• Autoimmune & Inflammation in vivo models
• Fibrosis
• Neuroscience & Rare Disease
• Pain
• Cardiovascular & Metabolic Disease
• Reproductive & Infectious Disease
• In vivo Imaging
• Tissue Analysis
• Biomarkers Capabilities and More...
When existing models don’t fit, we develop the precise model you require. Our expertise includes surgical, orthotopic, genetic, and
humanized models—all developed in close collaboration with your team to ensure they are biologically relevant and clinically useful.
Our portfolio includes syngeneic, xenograft, and humanized mouse models to assess tumor growth inhibition, immune checkpoint blockade, and combination immunotherapies. Each model is backed by detailed tumor kinetics, immune profiling, and PK/PD correlation data.
We offer in vivo models for autoimmune and inflammatory diseases including rheumatoid arthritis, asthma, colitis, and psoriasis. These models are supported by cytokine profiling, immune cell subset analysis, and histopathological endpoints to guide therapeutic validation.
This diverse category spans fertility and embryo implantation studies, LPS- and ovalbumin-induced respiratory inflammation, and pathogen-specific infectious disease models. All models are optimized for translational biomarker analysis and dose-response evaluation.
Our CNS platform includes validated models for Alzheimer's, Parkinson's, epilepsy, depression, and schizophrenia. Behavioural, histological, and neurochemical readouts allow comprehensive evaluation of neuroactive compounds across acute and chronic paradigms.
We offer acute nociceptive, inflammatory, neuropathic, and cancer pain models, including CFA, CCI, SNL, and bone cancer models. Endpoints include thermal/haptic sensitivity, functional recovery, and electrophysiological data to support analgesic development.
Our models include diet-induced obesity, STZ-induced and genetic models of diabetes, and isoproterenol-induced cardiac hypertrophy. With metabolic cage studies, glucose tolerance tests, lipid profiling, and echocardiography, we provide robust datasets for metabolic and cardiovascular drug development.
We offer model development and customized services tailored to your target, mechanism, and disease context.
We invite you to take a virtual tour of our in vivo pharmacology laboratories at Sai Life Sciences. Explore how our thoughtfully designed infrastructure—spanning AAALAC-accredited vivarium spaces, advanced disease models, and high-throughput capabilities—enables high-quality preclinical research with precision and scale.
A novel small molecule targeting hepatic receptors showed potent in vivo PD modulation at clinically relevant doses in diet-induced obesity models, providing critical proof-of-concept.
Sailife supported combination therapy efficacy in patient-derived xenografts, revealing synergistic tumor suppression and clear PK/PD correlations.
A novel small molecule targeting hepatic receptors showed potent in vivo PD modulation at clinically relevant doses in diet-induced obesity models, providing critical proof-of-concept.
Sailife supported combination therapy efficacy in patient-derived xenografts, revealing synergistic tumor suppression and clear PK/PD correlations.
At Sai Life Sciences, we offer customized scientific solutions and translational insights to meet your unique research needs.
As a globally trusted preclinical in vivo pharmacology partner, our experts provide high-quality, ethical research that drives your molecule forward with precision and care.
Extensive Model Library:
Over 200 validated models spanning oncology, CNS/neurology in vivo models, inflammation, metabolic disorder in vivo efficacy models, and more
Custom Model Development:
Tailored models to align with your molecule’s mechanism and therapeutic objectives
Comprehensive Study Execution:
From design and dosing to endpoint analysis and reporting, we manage the entire process
SOP-Led Operations:
Standard Operating Procedures ensure data integrity and reproducibility
Proven Expertise:
A successful track record with global biopharma and biotech clients
Connect with our scientific team or delve deeper into our in vivo capabilities.
Registered Office
DS-7, IKP Knowledge Park,
Turkapally Village,
Shameerpet Mandal,
Medchal-Malkajgiri District-500078,
Telangana, India
All rights reserved © 2025 Sai Life Sciences Limited